943601-78-3

Upstream product

• 1694-92-4 2-Nitrobenzenesulfonyl chloride 
• 153086-78-3 tert-butyl {2-[2-(2-aminoethoxy)ethoxy]ethyl}carbamate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 929-59-9 3,6-dioxa-1,8-diaminooctane 
• 112-27-6 2,2'-[1,2-ethanediylbis(oxy)]bisethanol 
• 201037-95-8 2-(2-(2-(tert-butyl-dimethyl-silanyloxy)-ethoxy)-ethoxy)-ethanol 
• 943601-23-8 N-(2-[2-{2-hydroxyethoxy}ethoxy]ethyl)-2-nitro-benzenesulfonamide 
• 943601-22-7 C₁₈H₃₂O₇SiSN₂ 
• 943601-24-9 (2-[2-azidoethoxy]ethyl)-N-nosylethanamine 

Downstream Products

• 943601-30-7 C₃₇H₄₉F₃N₁₀O₁₁S₂ 
• 943601-31-8 C₃₁H₄₆F₃N₉O₇S 
• 1571096-91-7 (S)-N-(2-(2-(2-(3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)-phenylsulfonamido)ethoxy)ethoxy)ethyl)-N-methyl-2-nitrobenzenesulfonamide 
• 1571096-88-2 tert-butyl (2-(2-(2-(N-methyl-2-nitrophenylsulfonamido)ethoxy)ethoxy)ethyl)carbamate 

Relevant academic research and scientific papers

COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS

The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist- induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders.

Convenient synthesis of photoaffinity probes and evaluation of their labeling abilities

Convenient synthesis of a variety of photoaffinity probes was accomplished by utilizing our Ns strategy and novel resin. The synthetic probes were evaluated via the labeling ability with the preseniline 1 C-terminal fragments, which was identified as a therapeutic target for Alzheimer's disease.